Jennifer Cooper

Twinlab Consolidation Corporation
Vice President of R&D and Quality

Jennifer Cooper is the Vice President of R&D and Quality at TCC. Previously, she was on the executive leadership board, M&A committee and served as the Director of Product and Business Development and Quality at US Pharmacia whose primary business interests are in Poland and Eastern Europe. While at US Pharmacia, Jennifer oversaw food supplements (natural products), traditional herbal medicines, medical devices and dermocosmetics. Prior to USP, Jennifer was Vice President of Research & Development and Quality at US based OTC company, Dynova Laboratories, for 5 years. Jennifer has experience managing all the technical functions for OTC/ natural products distributed in the mass and specialty markets: including regulatory affairs, product formulating and testing, contract manufacturing, scientific and clinical research, intellectual property and quality assurance. She has directed the development of natural products and/ or over-the-counter drugs in Europe, Asia, and North and Central America. Jennifer started her career at Twinlab where she held a variety of technical and positions, including heading up new product development during one of their biggest periods of growth. She has spent over 25 years in the natural product industry in the disciplines of quality, regulatory affairs and product development. Jennifer has held senior leadership roles in the US and internationally for the last 15 years. Ms. Cooper has developed and brought to market over 300 new products.


July 18, 2018

12:00 PM  -  1:00 PM

Palos Verdes Ballrooms 4&5

The Blurring Line Between Big Pharma and Nutraceuticals

The line between nutraceuticals, OTC and pharma is being redefined. Active and engaged on that blurring line, this panel of experts will explore what’s coming and how we might re-envision DSHEA to take the industry where it needs to go to realize the goal of changing healthcare. Defining the right science and how it fits … Continued

Click for more information on 'The Blurring Line Between Big Pharma and Nutraceuticals'